SG11201607918TA - Cancer treatment - Google Patents
Cancer treatmentInfo
- Publication number
- SG11201607918TA SG11201607918TA SG11201607918TA SG11201607918TA SG11201607918TA SG 11201607918T A SG11201607918T A SG 11201607918TA SG 11201607918T A SG11201607918T A SG 11201607918TA SG 11201607918T A SG11201607918T A SG 11201607918TA SG 11201607918T A SG11201607918T A SG 11201607918TA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer treatment
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983951P | 2014-04-24 | 2014-04-24 | |
| PCT/IB2015/052796 WO2015162532A1 (en) | 2014-04-24 | 2015-04-16 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607918TA true SG11201607918TA (en) | 2016-11-29 |
Family
ID=53398149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607918TA SG11201607918TA (en) | 2014-04-24 | 2015-04-16 | Cancer treatment |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20170184602A1 (ru) |
| EP (1) | EP3134119B1 (ru) |
| JP (1) | JP6603474B2 (ru) |
| KR (1) | KR101943177B1 (ru) |
| CN (1) | CN106233143B (ru) |
| AR (1) | AR100169A1 (ru) |
| AU (3) | AU2015249513A1 (ru) |
| BR (1) | BR112016024143A2 (ru) |
| CA (1) | CA2946362C (ru) |
| CY (1) | CY1120731T1 (ru) |
| DK (1) | DK3134119T3 (ru) |
| ES (1) | ES2691213T3 (ru) |
| HK (1) | HK1231561A1 (ru) |
| HU (1) | HUE040167T2 (ru) |
| IL (1) | IL247859B (ru) |
| MX (1) | MX2016013910A (ru) |
| PL (1) | PL3134119T3 (ru) |
| PT (1) | PT3134119T (ru) |
| RU (1) | RU2651469C1 (ru) |
| SG (1) | SG11201607918TA (ru) |
| SI (1) | SI3134119T1 (ru) |
| TR (1) | TR201815682T4 (ru) |
| TW (1) | TWI568439B (ru) |
| WO (1) | WO2015162532A1 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6945199B2 (ja) | 2017-05-19 | 2021-10-06 | 国立大学法人山口大学 | アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法 |
| EP3820522A4 (en) * | 2018-07-12 | 2022-05-18 | Corvus Pharmaceuticals, Inc. | METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY |
| CA3106038A1 (en) * | 2018-07-12 | 2020-01-16 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| US10586164B1 (en) | 2018-10-15 | 2020-03-10 | AIble Inc. | Interface for visualizing and improving model performance |
| US10936768B2 (en) * | 2018-10-15 | 2021-03-02 | Aible, Inc. | Interface for visualizing and improving model performance |
| US20220390456A1 (en) * | 2019-10-17 | 2022-12-08 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| WO2023217889A1 (en) * | 2022-05-11 | 2023-11-16 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of bmmf1 rep protein as diagnostic marker for lung cancer |
| WO2023217886A1 (en) * | 2022-05-11 | 2023-11-16 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of bmmf1 rep protein as diagnostic marker for pancreatic cancer and diabetes mellitus type 2 |
| WO2024026407A1 (en) * | 2022-07-28 | 2024-02-01 | The Board Of Regents Of The University Of Oklahoma | Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050095634A1 (en) | 2003-10-16 | 2005-05-05 | Genomic Health Inc. | qRT-PCR assay system for gene expression profiling |
| ES2550614T3 (es) * | 2004-04-09 | 2015-11-11 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
| US8383357B2 (en) * | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US20090221010A1 (en) * | 2005-10-21 | 2009-09-03 | Elting James J | Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy |
| US20070128636A1 (en) * | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
| KR20090046893A (ko) * | 2006-07-28 | 2009-05-11 | 노파르티스 아게 | 흑색종에서 치료학적 반응에 대한 조기 지표로서의 흑색종 억제 활성 (ｍｉａ) 단백질의 용도 |
| WO2008066755A2 (en) * | 2006-11-22 | 2008-06-05 | University Of Georgia Research Foundation, Inc. | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
| AU2010270227B2 (en) * | 2009-07-08 | 2015-01-22 | Worldwide Innovative Network | Method for predicting efficacy of drugs in a patient |
| BR112012005670A2 (pt) * | 2009-09-17 | 2017-01-10 | Hoffmann La Roche | ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso |
| US7736861B1 (en) * | 2009-10-19 | 2010-06-15 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| WO2012052757A1 (en) * | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| JP2014503500A (ja) * | 2010-11-18 | 2014-02-13 | シンタ ファーマスーティカルズ コーポレーション | 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択 |
| CN103957920B (zh) * | 2011-10-04 | 2018-04-20 | 因维维斯制药公司 | 用于鉴定和治疗抗黄体制剂敏感性肿瘤的方法和系统 |
| RU2659173C2 (ru) * | 2012-01-13 | 2018-06-28 | Дженентек, Инк. | Биологические маркеры для идентификации пациентов для лечения антагонистами vegf |
-
2015
- 2015-04-16 TR TR2018/15682T patent/TR201815682T4/tr unknown
- 2015-04-16 SI SI201530426T patent/SI3134119T1/sl unknown
- 2015-04-16 DK DK15729222.8T patent/DK3134119T3/en active
- 2015-04-16 PL PL15729222T patent/PL3134119T3/pl unknown
- 2015-04-16 WO PCT/IB2015/052796 patent/WO2015162532A1/en active Application Filing
- 2015-04-16 CN CN201580021401.8A patent/CN106233143B/zh not_active Expired - Fee Related
- 2015-04-16 EP EP15729222.8A patent/EP3134119B1/en active Active
- 2015-04-16 US US15/305,066 patent/US20170184602A1/en not_active Abandoned
- 2015-04-16 HU HUE15729222A patent/HUE040167T2/hu unknown
- 2015-04-16 MX MX2016013910A patent/MX2016013910A/es active IP Right Grant
- 2015-04-16 AU AU2015249513A patent/AU2015249513A1/en not_active Abandoned
- 2015-04-16 CA CA2946362A patent/CA2946362C/en not_active Expired - Fee Related
- 2015-04-16 PT PT15729222T patent/PT3134119T/pt unknown
- 2015-04-16 KR KR1020167029131A patent/KR101943177B1/ko active IP Right Grant
- 2015-04-16 ES ES15729222.8T patent/ES2691213T3/es active Active
- 2015-04-16 SG SG11201607918TA patent/SG11201607918TA/en unknown
- 2015-04-16 RU RU2016140271A patent/RU2651469C1/ru active
- 2015-04-16 BR BR112016024143A patent/BR112016024143A2/pt not_active Application Discontinuation
- 2015-04-22 JP JP2015087291A patent/JP6603474B2/ja not_active Expired - Fee Related
- 2015-04-23 AR ARP150101225A patent/AR100169A1/es unknown
- 2015-04-23 TW TW104113043A patent/TWI568439B/zh not_active IP Right Cessation
-
2016
- 2016-09-16 IL IL247859A patent/IL247859B/en active IP Right Grant
-
2017
- 2017-05-24 HK HK17105244.4A patent/HK1231561A1/zh unknown
-
2018
- 2018-05-03 AU AU2018203086A patent/AU2018203086A1/en not_active Abandoned
- 2018-10-05 CY CY181101033T patent/CY1120731T1/el unknown
-
2019
- 2019-03-01 US US16/290,827 patent/US20190331687A1/en not_active Abandoned
-
2020
- 2020-01-13 AU AU2020200237A patent/AU2020200237A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL247859B (en) | 2020-07-30 |
| BR112016024143A2 (pt) | 2017-08-15 |
| EP3134119B1 (en) | 2018-08-22 |
| TW201545747A (zh) | 2015-12-16 |
| MX2016013910A (es) | 2017-01-11 |
| CN106233143B (zh) | 2020-01-21 |
| AU2020200237A1 (en) | 2020-02-06 |
| CA2946362A1 (en) | 2015-10-29 |
| CY1120731T1 (el) | 2019-12-11 |
| JP2015210268A (ja) | 2015-11-24 |
| WO2015162532A1 (en) | 2015-10-29 |
| HUE040167T2 (hu) | 2019-02-28 |
| PL3134119T3 (pl) | 2018-12-31 |
| KR20160134817A (ko) | 2016-11-23 |
| JP6603474B2 (ja) | 2019-11-06 |
| AR100169A1 (es) | 2016-09-14 |
| EP3134119A1 (en) | 2017-03-01 |
| DK3134119T3 (en) | 2018-10-22 |
| CA2946362C (en) | 2019-03-12 |
| IL247859A0 (en) | 2016-11-30 |
| TR201815682T4 (tr) | 2018-11-21 |
| RU2651469C1 (ru) | 2018-04-19 |
| ES2691213T3 (es) | 2018-11-26 |
| US20170184602A1 (en) | 2017-06-29 |
| CN106233143A (zh) | 2016-12-14 |
| SI3134119T1 (sl) | 2018-11-30 |
| US20190331687A1 (en) | 2019-10-31 |
| PT3134119T (pt) | 2018-11-07 |
| TWI568439B (zh) | 2017-02-01 |
| HK1231561A1 (zh) | 2017-12-22 |
| KR101943177B1 (ko) | 2019-01-28 |
| AU2018203086A1 (en) | 2018-05-24 |
| AU2015249513A1 (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201702382B (en) | Combination therapy for cancer | |
| HUE053654T2 (hu) | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére | |
| HK1231381A1 (zh) | 癌症組合療法 | |
| HK1231561A1 (zh) | 癌症治療 | |
| IL246761A0 (en) | Combined cancer treatment | |
| GB201409363D0 (en) | Skin cancer treatment | |
| GB201408297D0 (en) | Treatment of cancer | |
| HK1251794A1 (zh) | 癌症治療 | |
| GB201508480D0 (en) | Cancer | |
| GB201411027D0 (en) | Treatment | |
| GB201522433D0 (en) | Cancer treatment | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201412411D0 (en) | Treatment | |
| GB201411884D0 (en) | Cancer therapy | |
| GB201413317D0 (en) | Atheroscierosis treatment | |
| GB201412410D0 (en) | Treatment | |
| GB201409362D0 (en) | Treatment of cancer | |
| GB201405449D0 (en) | Treatment of cancer | |
| GB201417719D0 (en) | New treatment | |
| GB201405075D0 (en) | Treatment of cancer | |
| GB201400241D0 (en) | Treatment | |
| GB201400240D0 (en) | Treatment | |
| GB201400239D0 (en) | Treatment | |
| GB201400235D0 (en) | Treatment | |
| GB201400238D0 (en) | Treatment |